---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205187"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:30:27.850673+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Q1 net loss widens to $63.5M; bitopertin Phase 3 enrollment complete

## Summary
- Net loss $63.5M vs $34.1M YoY; R&D expenses rose to $45.9M, SG&A to $23.6M.
- Cash and securities $730.2M at March 31, 2026, funding operations into 2029.
- Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (N=183); topline data Q4 2026.
- Updated Phase 2 DISC-0974 (MF anemia) data to be presented at ASCO June 2026 (N=61).
- Phase 2 DISC-3405 (PV) and Phase 1b (SCD) data both expected in Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-205187
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/0001193125-26-205187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205187
- JSON: https://secwatch.observer/filing/0001193125-26-205187.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205187.txt

## Key facts
- Earnings Releases
  Disc Medicine, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $63.5 million for the three months ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss was $63.5 million for the three months ended March 31, 2026
  - Result: reported results
  source text: On May 5, 2026, Disc Medicine, Inc. announced its financial results for the first quarter ended March 31, 2026 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/0001193125-26-205187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.